Gemtuzumab ozogamicin (marketed as Mylotarg) is a monoclonal antibody used to treat acute myelogenous leukemia. Monoclonal antibodies (mAb) are antibodies that are identical because they were produced by one type of immune cell, all clones of a single parent cell. ... Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a cancer of the myeloid line of blood cells. ...
It is a monoclonal antibody to CD33 linked to a cytotoxic agent, calicheamicin. CD33 is expressed in most leukemic blast cells but is not found on normal hematopoietic stem cells. When given to patients in first relapse, 15% of patients achieve a complete remission. Mouse embryonic stem cells. ...
A notable complication of therapy with gemtuzumab is the increased risk of veno-occlusive disease in patients who go on to receive bone marrow transplantation. Veno-occlusive disease (VOD) is a disease affecting the liver. ... Bone marrow transplantation is a medical procedure that involves stem cell transplantation. ...
Gemtuzumabozogamicin is a new treatment option for patients with relapsed AML and is approved for patients 60 and older who are not candidates for conventional chemotherapy.
Gemtuzumabozogamicin is indicated for the treatment of patients with CD33+ AML in first relapse who are 60 or older and are not considered candidates for conventional cytotoxic chemotherapy.
Because gemtuzumabozogamicin is sensitive to light, it must be protected from direct and indirect sunlight and fluorescent light during preparation and administration of the infusion.
Gemtuzumabozogamicin is used to treat patients with CD33 positive acute myeloid leukemia (AML) in first relapse who are 60 years of age or older and for whom other chemotherapy is not recommenced.
The amount of gemtuzumabozogamicin that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition being treated.
Gemtuzumabozogamicin Consists of a chemotherapy drug, calicheamicin, attached to a monoclonal antibody that targets the CD33 antigen, found on leukemic blast cells in more than 80% of patients with acute myelogenous leukemia (AML), as well as normal myeloid cells.
Feeds |
Contact